Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW10508 for major depressive disorder
ACTRN12625000128493Phase 2Not yet recruiting
- Sponsor
- XWPharma
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing XW10508 with Placebo (2 arms). Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale score from baseline. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
XW10508
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12625000128493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000128493.